Cover Image
Market Research Report

North America PDX Models Market: Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

Published by Data Bridge Market Research Private Limited Product code 674773
Published Content info 100 Pages
Delivery time: 1-2 business days
Price
Back to Top
North America PDX Models Market: Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025
Published: July 1, 2018 Content info: 100 Pages
Description

North America PDX models market is expected to hold the leading market share in the forecast period of 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Prominent factors driving the growth of this market consist of rising number of pharmaceutical R&D activities in cancer research, advantages offered by PDX models offer compared with the classic approach, rising need for personalized medicine and increasing support for cancer research activities from government and non-government organization.

The key market players for North America PDX models market are listed below:

  • Crown Bioscience Inc.
  • The Jackson Laboratory
  • Champion Oncology, Inc.
  • Charles River
  • Oncodesign
  • Wuxi AppTec
  • Horizon Discovery Group plc
  • Pharmatest Services
  • Hera Biolabs
  • EPO Berlin-Buch GmbH
  • Xentech
  • Urolead
  • Creative Animodel
  • EUROPDX
  • MI Bioresearch Inc
  • Aragen Bioscience

The market is further segmented into:

  • Type
  • Tumor Type
  • Application
  • End User

The North America PDX models market is segmented based on type into two notable segments; mice models and rat models. In 2018, mice models segment is valued to rule with the highest market share by 2025.

The North America PDX models market is segmented in tumor type categories into six notable segments; respiratory tumor models, urological tumor models, gastrointestinal tumor models, hematological tumor models, gynecological tumor models and others. In 2018, respiratory tumor models segment is valued to rule with the highest market shares by 2025, rising at the highest CAGR.

The North America PDX models market is segmented in application into preclinical drug development and oncology research and biomarker analysis. In 2018, preclinical drug development and oncology research segment is valued to rule with highest market shares and rising at the highest CAGR.

The North America PDX models market is segmented in end user into contract research organization (CRO), academic and research institutions and pharmaceutical and biotechnology companies. In 2018, contract research organization (CRO) segment is valued to rule with highest market shares and rising at the highest CAGR.

Based on geography, the market is segmented into:

  • U.S.
  • Canada
  • Mexico

Covered in this report

The report covers the present scenario and the growth prospects of the North America PDX models for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION 10

  • 1.1 OBJECTIVES OF THE STUDY 10
  • 1.2 MARKET DEFINITION 10
  • 1.3 OVERVIEW OF NORTH AMERICA PDX MODELS MARKET 10
  • 1.4 CURRENCY AND PRICING 11
  • 1.5 LIMITATION 11
  • 1.6 MARKETS COVEREDSS 11

2 MARKET SEGMENTATION 13

  • 2.1 MARKETS COVERED 13
  • 2.2 GEOGRAPHIC SCOPE 14
  • 2.3 YEARS CONSIDERED FOR THE STUDY 14
  • 2.4 CURRENCY AND PRICING 15
  • 2.5 RESEARCH METHODOLOGY 16
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 19
  • 2.7 SECONDARY SOURCES 20
  • 2.8 ASSUMPTIONS 20

3 MARKET OVERVIEW 21

  • 3.1 DRIVERS 23
    • 3.1.1 RISING NUMBER OF PHARMACEUTICAL R&D ACTIVITIES IN CANCER RESEARCH 23
    • 3.1.2 PDX MODELS OFFER ADVANTAGES AS COMPARED WITH THE CLASSIC APPROACH 25
    • 3.1.3 RISING NEED FOR PERSONALIZED MEDICINE 26
    • 3.1.4 INCREASING SUPPORT FOR CANCER RESEARCH ACTIVITIES FROM GOVERNMENT AND NON-GOVERNMENT ORGANIZATION 26
  • 3.2 RESTRAINTS 27
    • 3.2.1 HIGH COST OF PDX MODELS 27
    • 3.2.2 STRICT REGULATION WITH RESPECT TO THE UTILIZATION OF ANIMAL MODELS IN CANCER RESEARCH 27
  • 3.3 OPPRTUNITIES 28
    • 3.3.1 INCREASING DEMAND FOR HUMANIZED PDX MODELS 28
  • 3.4 CHALLENGES 29
    • 3.4.1 LIMITATIONS OF PDX MODELS 29

4 EXECUTIVE SUMMARY 30

5 PREMIUM INSIGHTS 32

6 NORTH AMERICA PDX MODELS MARKET, BY TYPE 35

  • 6.1 OVERVIEW 36
  • 6.2 MICE MODELS 38
  • 6.3 RAT MODELS 39

7 NORTH AMERICA PDX MODELS MARKET, BY TUMOR TYPE 40

  • 7.1 OVERVIEW 41
  • 7.2 GASTROINTESTINAL TUMOR MODELS 43
  • 7.3 GYNECOLOGICAL TUMOR MODELS 44
  • 7.4 RESPIRATORY TUMOR MODELS 45
  • 7.5 UROLOGICAL TUMOR MODELS 46
  • 7.6 HEMATOLOGICAL TUMOR MODELS 47
  • 7.7 OTHERS 48

8 NORTH AMERICA PDX MODELS MARKET, BY APPLICATION 49

  • 8.1 OVERVIEW 50
  • 8.2 PRECLINICAL DRUG DEVELOPMENT AND ONCOLOGY RESEARCH 52
  • 8.3 BIOMARKER ANALYSIS 53

9 NORTH AMERICA PDX MODELS MARKET, BY END USER 54

  • 9.1 OVERVIEW 55
  • 9.2 CONTRACT RESEARCH ORGANIZATIONS 57
  • 9.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 58
  • 9.4 ACADEMIC AND RESEARCH INSTITUTIONS 59

10 NORTH AMERICA PDX MODELS MARKET, BY GEOGRAPHY 60

  • 10.1 NORTH AMERICA 60
    • 10.1.1 U.S. 69
    • 10.1.2 CANADA 71
    • 10.1.3 MEXICO 73

11 NORTH AMERICA PDX MODELS MARKET, COMPANY LANDSCAPE 75

  • 11.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 75

12 COMPANY PROFILES 76

  • 12.1 CHARLES RIVER 76
    • 12.1.1 COMPANY OVERVIEW 76
    • 12.1.2 REVENUE ANALYSIS 76
    • 12.1.3 COMPANY SHARE ANALYSIS 77
    • 12.1.4 PRODUCT PORTFOLIO 77
    • 12.1.5 RECENT DEVELOPMENTS 77
  • 12.2 CROWN BIOSCIENCE INC. (SUBSIDIARY OF JSR CORPORATION) 78
    • 12.2.1 COMPANY OVERVIEW 78
    • 12.2.2 GEOGRAPHIC PRESENCE 78
    • 12.2.3 COMPANY SHARE ANALYSIS 79
    • 12.2.4 PRODUCT PORTFOLIO 79
    • 12.2.5 RECENT DEVELOPMENTS 80
  • 12.3 CHAMPION ONCOLOGY, INC 81
    • 12.3.1 COMPANY OVERVIEW 81
    • 12.3.2 REVENUE ANALYSIS 81
    • 12.3.3 COMPANY SHARE ANALYSIS 82
    • 12.3.4 PRODUCT PORTFOLIO 82
    • 12.3.5 RECENT DEVELOPMENTS 82
  • 12.4 ARAGEN BIOSCIENCE (SUBSIDIARY OF GVK BIOSCIENCES PRIVATE LIMITED) 83
    • 12.4.1 COMPANY OVERVIEW 83
    • 12.4.2 PRODUCT PORTFOLIO 83
    • 12.4.3 RECENT DEVELOPMENTS 83
  • 12.5 CREATIVE ANIMODEL 84
    • 12.5.1 COMPANY OVERVIEW 84
    • 12.5.2 PRODUCT PORTFOLIO 84
    • 12.5.3 RECENT DEVELOPMENTS 84
  • 12.6 EPO BERLIN-BUCH GMBH 85
    • 12.6.1 COMPANY OVERVIEW 85
    • 12.6.2 PRODUCT PORTFOLIO 85
    • 12.6.3 RECENT DEVELOPMENTS 85
  • 12.7 EUROPDX 86
    • 12.7.1 COMPANY OVERVIEW 86
    • 12.7.2 GEOGRAPHICAL PRESENCE 86
    • 12.7.3 PRODUCT PORTFOLIO 87
    • 12.7.4 RECENT DEVELOPMENTS 87
  • 12.8 HERA BIOLABS 88
    • 12.8.1 COMPANY OVERVIEW 88
    • 12.8.2 PRODUCT PORTFOLIO 88
    • 12.8.3 RECENT DEVELOPMENTS 88
  • 12.9 HORIZON DISCOVERY GROUP PLC 89
    • 12.9.1 COMPANY OVERVIEW 89
    • 12.9.2 REVENUE ANALYSIS 89
    • 12.9.3 PRODUCT PORTFOLIO 90
    • 12.9.4 RECENT DEVELOPMENTS 90
  • 12.10 MI BIORESEARCH INC 91
    • 12.10.1 COMPANY OVERVIEW 91
    • 12.10.2 PRODUCT PORTFOLIO 91
    • 12.10.3 RECENT DEVELOPMENTS 91
  • 12.11 ONCODESIGN 92
    • 12.11.1 COMPANY OVERVIEW 92
    • 12.11.2 REVENUE ANALYSIS 92
    • 12.11.3 PRODUCT PORTFOLIO 93
    • 12.11.4 RECENT DEVELOPMENTS 93
  • 12.12 PHARMATEST SERVICES LTD 94
    • 12.12.1 COMPANY OVERVIEW 94
    • 12.12.2 GEOGRAPHIC PRESENCE 94
    • 12.12.3 PRODUCT PORTFOLIO 95
    • 12.12.4 RECENT DEVELOPMENTS 95
  • 12.13 THE JACKSON LABORATORY 96
    • 12.13.1 COMPANY OVERVIEW 96
    • 12.13.2 REVENUE ANALYSIS 96
    • 12.13.3 PRODUCT PORTFOLIO 97
    • 12.13.4 RECENT DEVELOPMENTS 97
  • 12.14 UROLEAD 98
    • 12.14.1 COMPANY OVERVIEW 98
    • 12.14.2 PRODUCT PORTFOLIO 98
    • 12.14.3 RECENT DEVELOPMENTS 98
  • 12.15 WUXI APPTEC 99
    • 12.15.1 COMPANY OVERVIEW 99
    • 12.15.2 GEOGRAPHIC PRESENCE 99
    • 12.15.3 PRODUCT PORTFOLIO 100
    • 12.15.4 RECENT DEVELOPMENTS 100
  • 12.16 XENTECH 101
    • 12.16.1 COMPANY OVERVIEW 101
    • 12.16.2 PRODUCT PORTFOLIO 101
    • 12.16.3 RECENT DEVELOPMENTS 101

13 RELATED REPORTS 102

LIST OF TABLES

  • TABLE 1 NORTH AMERICA PDX MODELS MARKET, BY TYPE, 2016- 2025, (USD MILLION) 37
  • TABLE 2 NORTH AMERICA MICE MODELS IN PDX MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 38
  • TABLE 3 NORTH AMERICA RAT MODELS IN PDX MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 39
  • TABLE 4 NORTH AMERICA PDX MODELS MARKET, BY TUMOR TYPE, 2016- 2025 (USD MILLION) 42
  • TABLE 5 NORTH AMERICA GASTROINTESTINAL TUMOR MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 43
  • TABLE 6 NORTH AMERICA GYNECOLOGICAL TUMOR MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 44
  • TABLE 7 NORTH AMERICA RESPIRATORY TUMOR MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 45
  • TABLE 8 NORTH AMERICA UROLOGICAL TUMOR MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 46
  • TABLE 9 NORTH AMERICA HEMATOLOGICAL TUMOR MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 47
  • TABLE 10 NORTH AMERICA OTHERS TUMOR TYPES IN PDX MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 48
  • TABLE 11 NORTH AMERICA PDX MODELS MARKET, BY APPLICATION, 2016- 2025 (USD MILLION) 51
  • TABLE 12 NORTH AMERICA PRECLINICAL DRUG DEVELOPMENT AND ONCOLOGY RESEARCH IN PDX MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 52
  • TABLE 13 NORTH AMERICA BIOMARKER ANALYSIS IN PDX MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 53
  • TABLE 14 NORTH AMERICA PDX MODELS MARKET, BY END USER, 2016- 2025, (USD MILLION) 56
  • TABLE 15 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS IN PDX MODEL MARKET, BY REGION, 2016-2025, (USD MILLION) 57
  • TABLE 16 NORTH AMERICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PDX MODELS MARKET, BY REGION, 2016-2025, (USD MILLION) 58
  • TABLE 17 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTIONS IN PDX MODELA MARKET, BY REGION, 2016-2025, (USD MILLION) 59
  • TABLE 18 NORTH AMERICA PDX MODELS MARKET, BY COUNTRY, 2016 - 2025, (USD MILLION) 66
  • TABLE 19 NORTH AMERICA PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 66
  • TABLE 20 NORTH AMERICA PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 67
  • TABLE 21 NORTH AMERICA PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 67
  • TABLE 22 NORTH AMERICA PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 68
  • TABLE 23 U.S. PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 69
  • TABLE 24 U.S. PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 69
  • TABLE 25 U.S. PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 70
  • TABLE 26 U.S. PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 70
  • TABLE 27 CANADA PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 71
  • TABLE 28 CANADA PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 71
  • TABLE 29 CANADA PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 72
  • TABLE 30 CANADA PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 72
  • TABLE 31 MEXICO PDX MODELS MARKET, BY TYPE, 2016 - 2025, (USD MILLION) 73
  • TABLE 32 MEXICO PDX MODELS MARKET, BY TUMOR TYPE, 2016 - 2025, (USD MILLION) 73
  • TABLE 33 MEXICO PDX MODELS MARKET, BY APPLICATION, 2016 - 2025, (USD MILLION) 74
  • TABLE 34 MEXICO PDX MODELS MARKET, BY END USER, 2016 - 2025, (USD MILLION) 74

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA PDX MODELS MARKET: SEGMENTATION 13
  • FIGURE 2 NORTH AMERICA PDX MODELS MARKET: DATA TRIANGULATION 16
  • FIGURE 3 NORTH AMERICA PDX MODELS MARKET: RESEARCH SNAPSHOT 17
  • FIGURE 4 NORTH AMERICA PDX MODELS MARKET : BOTTOM UP APPROACH 18
  • FIGURE 5 NORTH AMERICA PDX MODELS MARKET : TOP DOWN APPROACH 18
  • FIGURE 6 NORTH AMERICA PDX MODELS MARKET: INTERVIEW DEMOGRAPHICS 19
  • FIGURE 7 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF PDX MODELS MARKET 22
  • FIGURE 8 BELOW MENTIONED IS R&D EXPENSE BY THE JACKSON LABORATORY FOR YEAR 2016-17: 24
  • FIGURE 9 NORTH AMERICA PDX MODELS MARKET: SEGMENTATION 31
  • FIGURE 10 RISING NUMBER OF PHARMACEUTICAL R&D ACTIVITIES IN CANCER RESEARCH AND RISING NEED FOR PERSONALIZED MEDICINE ARE EXPECTED TO DRIVE THE MARKET FOR PDX MODELS IN THE FORECAST PERIOD 2018 TO 2025 32
  • FIGURE 11 MICE MODELS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA PDX MODELS MARKET IN 2018 & 2025 33
  • FIGURE 12 ASIA PACIFIC IS THE MAXIMUM GROWING AND MOST PROFITABLE REVENUE POCKETS FOR PDX MODELS MARKET IN THE FORECAST PERIOD FROM 2018 TO 2025 34
  • FIGURE 13 NORTH AMERICA PDX MODELS MARKET: BY TYPE, 2017 36
  • FIGURE 14 NORTH AMERICA PDX MODELS MARKET: BY TYUMOR TYPE, 2017 41
  • FIGURE 15 NORTH AMERICA PDX MODELS MARKET: BY APPLICATION, 2017 50
  • FIGURE 16 NORTH AMERICA PDX MODELS MARKET: BY END USER, 2017 55
  • FIGURE 17 NORTH AMERICA PDX MODELS MARKET SNAPSHOT (2017) 60
  • FIGURE 18 NORTH AMERICA PDX MODELS MARKET: BY COUNTRY (2017) 62
  • FIGURE 19 NORTH AMERICA PDX MODELS MARKET: BY COUNTRY (2018 & 2025) 63
  • FIGURE 20 NORTH AMERICA PDX MODELS MARKET: BY COUNTRY (2017 & 2025) 64
  • FIGURE 21 NORTH AMERICA PDX MODELS MARKET, BY TYPE (2018 - 2025) 65
  • FIGURE 22 NORTH AMERICA PDX MODELS MARKET: COMPANY SHARE 2017(%) 75
Back to Top